Importantly, treatment-induced transient hyperinsulinemia is a major driver of reduced efficacy of PI3K/Akt/mTOR inhibitors, promoting glycogen breakdown and inhibition of glucose uptake, resulting in hyperglycemia (22, 23). This evidence concerns the gene PIK3CA and Hyperglycemia.